Is there an approved retatrutide product?

No. It is investigational everywhere, so there is no licensed manufacturer, only a trial sponsor.

Is research material made by Lilly?

No. It is synthesised by peptide manufacturers and supplied for laboratory use, with no connection to the trial programme.

Who Makes Retatrutide?

The short answer

Retatrutide is developed by Eli Lilly and Company under the internal code LY3437943. No licensed retatrutide product exists anywhere, so there is no manufacturer of an approved medicine, only a sponsor running clinical trials.

Key facts

Developer: Eli Lilly and Company
Internal code: LY3437943
Other Lilly incretins: Tirzepatide, orforglipron, dulaglutide
Licensed product: None
Trial sponsor: Eli Lilly
Signalled filing: FDA, Q1 2027

The LY prefix

LY is Eli Lilly's development prefix, the same convention as NNC for Novo Nordisk, BI for Boehringer Ingelheim and CJC for ConjuChem. Seeing LY3437943 in a paper identifies the sponsor immediately, and this is useful to know because Lilly's incretin portfolio is unusually crowded: tirzepatide is LY3298176 and orforglipron is LY3502970.

Why the portfolio matters for reading the data

Lilly develops retatrutide, tirzepatide and orforglipron simultaneously, and they compete with each other. TRIUMPH-5 compares retatrutide against tirzepatide. A company running a head-to-head between two of its own compounds is an informative design, because there is no incentive to disadvantage either.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £49.99

The confusion this creates

Three Lilly incretins with similar codes is a recipe for mixed-up citations, and this library found exactly that: a PubChem record for tirzepatide cited as retatrutide, and a trial registration for orforglipron's ATTAIN-1 labelled as retatrutide's TRIUMPH-1. Both were plausible-looking and both were wrong. Checking the compound named in a record, not just its number, is the defence.

There is no manufacturer of a product

Because no retatrutide product is licensed anywhere, there is no approved manufacturer. Material described as retatrutide and sold outside clinical trials does not originate from Lilly and has no connection to the compound in the TRIUMPH programme beyond the sequence it claims to be.

What that means here

Research material supplied under this name is synthesised by peptide manufacturers, characterised by a certificate of analysis, and supplied for laboratory use. It is not the trial compound, not a licensed medicine, and not connected to Eli Lilly.

Frequently asked questions

Who develops retatrutide?: Eli Lilly and Company, under the internal code LY3437943.
Is there an approved retatrutide product?: No. It is investigational everywhere, so there is no licensed manufacturer, only a trial sponsor.
Is research material made by Lilly?: No. It is synthesised by peptide manufacturers and supplied for laboratory use, with no connection to the trial programme.

Extended research context

The Retatrutide Research deep dive

Deep dive: how the triple-agonist scaffold was engineered

Retatrutide's 39-residue backbone was designed by Eli Lilly's peptide chemistry team to preserve the pharmacophores of three glucagon-family receptors on a single chain. The N-terminal domain retains GIP-receptor contacts, mid-chain substitutions restore GLP-1-receptor affinity lost in native GIP, and additional residue swaps confer glucagon-receptor engagement. A γGlu-2xOEG linker anchors a C20 fatty diacid at Lys17, which reversibly binds serum albumin and slows renal clearance. This is the same albumin-tethering strategy Novo Nordisk pioneered with semaglutide and Lilly refined further in tirzepatide.

The TRIUMPH Phase 3 programme in context

TRIUMPH is Lilly's global Phase 3 development umbrella for retatrutide, spanning obesity (TRIUMPH-1 through TRIUMPH-4), type 2 diabetes, MASH (metabolic dysfunction-associated steatohepatitis), and knee osteoarthritis linked to obesity. Readouts began in 2025 and continue through 2026. Because the compound is investigational, no regulator (FDA, EMA, or MHRA) has issued marketing authorisation, and legitimate supply exists only for laboratory reference and research contexts, never for human administration.

How retatrutide differs from tirzepatide and semaglutide at the mechanism level

Semaglutide is a mono-agonist (GLP-1 only). Tirzepatide is a dual agonist (GIP + GLP-1). Retatrutide adds glucagon-receptor activity, which pre-clinical and Phase 2 data suggest contributes to energy expenditure in addition to appetite regulation and glucose-dependent insulin release. This three-receptor combination is why retatrutide is sometimes called a 'metabolic multi-tool' peptide in the trade press, but the pharmacology is more nuanced than the label implies.

Research applications

▸In vitro receptor-binding assays across GIP-R, GLP-1R and GCGR panels
▸Comparator studies alongside semaglutide, tirzepatide and liraglutide reference standards
▸Analytical-method development: HPLC retention profiling and LC-MS confirmation
▸Stability testing of lipidated 39-residue peptides in aqueous and lyophilised forms
▸Reference material for teaching incretin pharmacology in university-level courses

Handling checklist

✓Store lyophilised vials at −20 °C; protect from light and humidity
✓Reconstitute with bacteriostatic water; avoid vortexing (foams the peptide)
✓Once reconstituted, store at 2–8 °C and use within 28 days
✓Verify batch CoA: HPLC ≥98%, mass matches ~4,731 Da, endotoxin low
✓Do not administer to humans or animals. Research use only

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Confusing retatrutide with tirzepatide in supplier catalogues

Fix: Cross-check the LY code (LY3437943 = retatrutide; LY3298176 = tirzepatide) and the receptor profile on the CoA.

✗ Using tap or filtered water for reconstitution

Fix: Only use bacteriostatic water for injection (0.9% benzyl alcohol) or sterile water, never lab DI water.

✗ Storing reconstituted solution at room temperature

Fix: Refrigerate at 2–8 °C immediately after reconstitution; discard after 28 days.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

UKP

Written and reviewed by

The UK Peptides Editorial Team · Research library, UK Peptides

The editorial team is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate. Corrections are made in place and the review date updated.

How we write and check this content Report a factual error in this article

Popular across the research hub

One flagship guide from every other research category.

← Back to Forum

Who Develops Retatrutide?